ovarian cancer

Overview

Ovarian cancer is a malignant neoplasm arising from the tissues of the ovary and represents the deadliest gynecological malignancy worldwide. It is most commonly classified by histological subtype, with high-grade serous ovarian cancer (HGSOC) accounting for the majority of cases and carrying the worst prognosis. The disease is often described as a "silent killer" due to its nonspecific early symptoms, which result in the majority of diagnoses occurring at advanced stages when peritoneal dissemination has already taken place. Ovarian cancer is the fourth leading cause of cancer deaths in women, and approximately half of women diagnosed with HGSOC succumb to the disease annually. Key risk factors include a higher number of lifetime ovulatory cycles, germline mutations in homologous recombination repair genes, and hereditary predisposition syndromes.

The molecular landscape of ovarian cancer is characterized by significant heterogeneity, encompassing alterations in DNA damage repair pathways, immune evasion mechanisms, metabolic reprogramming, and epigenetic dysregulation. Standard first-line treatment consists of cytoreductive surgery followed by platinum-based chemotherapy, typically combined with paclitaxel. However, platinum resistance is a frequent and clinically devastating phenomenon that contributes heavily to poor patient outcomes, driving extensive research into novel therapeutic strategies including PARP inhibitors, checkpoint inhibitor, and targeted agents addressing the tumor microenvironment.

Focus of Latest Publications

Recent publications on ovarian cancer have focused on improving diagnosis, prognostic stratification, and therapeutic targeting. One study developed a deep learning model to support real-time intraoperative identification of malignant ovarian tumors from gross specimen images, addressing the challenge of distinguishing malignant from benign tumors during surgery. Another study examined the cervico-vaginal DNA methylation WID-qEC test and found that, in women without endometrial or cervical cancer, test positivity was associated with ovarian cancer presence and with a higher number of lifetime ovulatory cycles, suggesting potential value for ovarian cancer triage in selected settings.

Several reports explored biomarkers and molecular features linked to ovarian cancer behavior. In a large cohort study of breast and ovarian cancer, low DHX37 protein expression in ovarian cancer was associated with lower FIGO stage, absence of residual disease, and improved overall survival, indicating a favorable prognostic association in this disease. A separate multi-omics and pan-cancer analysis identified shared molecular signatures across breast, ovarian, and colorectal cancers, highlighting Aurora kinase A, cyclin dependent kinase 1, and CCNB1 as hub targets and proposing AMG-900 as a candidate multitarget agent based on in silico binding, molecular dynamics, and pharmacokinetic analyses, although the authors emphasized the need for experimental and clinical validation.

Other studies addressed the ovarian cancer microenvironment and therapeutic modulation. Clonal lineage tracing using somatic mitochondrial DNA mutations and single-cell chromatin accessibility profiling in matched tumors, tissues, and blood from patients with lung and ovarian cancers showed that tumor microenvironment-resident myeloid cells, including macrophages and type 3 dendritic cells, were clonally related to circulating and tissue-infiltrating monocytes, with evidence that distinct differentiation fates may be programmed before infiltration. In a separate immunotherapy-oriented study, metabolite-sensing receptors such as GPR183 were identified as enhancers of natural killer (NK) cell and T cell infiltration and chemotaxis to breast and ovarian cancers, and receptor engineering increased tumor infiltration and control in preclinical models.

Therapeutic and mechanistic work also included a study of Yiyi Fuzi Baijiang Powder, which aimed to define its anti-ovarian cancer effects and implicated the JNK/c-Jun signaling pathway together with modulation of the tumor inflammatory microenvironment. In addition, a multicenter study in Japanese patients with ovarian cancer investigated risk factors for severe niraparib-induced anemia during maintenance therapy after platinum-based chemotherapy, reflecting ongoing efforts to optimize the safety of this treatment.